All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Predictive biomarkers are the foundation of precision medicine. The identification of predictive biomarkers is an important scientific component in advancing the drug discovery and development pipeline. With advances in biotechnology, several high-throughput methods have been utilized for predictive biomarker discovery, to elucidate the etiology and molecular mechanisms of cancers.
Creative Biolabs has organized a staff of outstanding scientists who have engaged in predictive biomarker discovery for many years. Our innovative predictive biomarker discovery strategies facilitate the integration of patient-centric multi-omics and clinical data; towards the early identification of novel disease biomarkers. By leveraging the wealth of information that we have on predictive biomarker discovery, we are pleased to help you with your study.
Support for the development of predictive biomarkers for drug response is wide and varied. These considerations are relevant to many recently developed cancer drugs that target discrete molecular aberrations, which are usually effective on only a subset of patients. The changing pharmacoeconomic environment and the increasing cost of drugs make predictive biomarkers more and more important. One important advantage of predictive biomarkers is the reduction in unnecessary treatment and adverse effects. Identification of predictive biomarkers as a companion diagnostic becomes a more common guideline and general practice. Therefore, there is an increasing need for the discovery of predictive biomarkers to allow patients with responsive diseases to be identified and treated accordingly.
Table 1. Examples of predictive biomarkers for drug response. (La Thangue, 2011)
Biomarker | Cancer type | Drug therapy | Drug target |
HER2 (gene amplification) | Breast | Trastuzumab | HER2 |
Estrogen receptor (protein expression) | Breast | Tamoxifen | Estrogen receptor |
BCR–ABL (gene translocation) | Chronic myeloid leukemia | Imatinib, dasatinib, nilotinib | BCR–ABL |
EGFR ± KRAS (KRAS mutation) | Colorectal cancer | Cetuximab, panitumumab | EGFR |
EGFR (kinase domain mutation) | Non-small-cell lung cancer | Erlotinib, gefitinib | EGFR |
PML–RAR (gene translocation) | Acute promyelocytic leukemia | All trans retinoic acid | PML–RAR |
BRCA1/2 (mutation) | Breast | Olaparib, veliparib | PARP |
BRAF V600E (mutation) | Melanoma | Vemurafenib | BRAF |
ALK (rearrangements) | Non-small-cell lung cancer | Crizotinib | ALK |
Powered by our advanced platforms and experienced technical personnel, Creative Biolabs has perfected our technical pipelines in the discovery of predictive biomarkers. A variety of different high-throughput approaches are available for biomarker discovery, including Single-nucleotide Polymorphism Analysis, transcript profiling by Gene Expression Microarray, and next-generation sequencing (NGS) methods, such as Tumor Mutational Burden (TMB), Neoantigen Load Analysis, Microsatellite Instability (MSI), T Cell Receptor (TCR) Repertoire Sequencing. Through our high-throughput system, functionally relevant cancer biomarkers can be identified, which can then be rationalized in the context of the mechanism of tumor cell killing, and used to support its clinical development.
Creative Biolabs also has developed in silico methodologies to identify predictive biomarkers for a specific type of purpose. Our scientists especially focus on the study of disease-related biomarkers, towards the early identification of novel bio-available markers.
With our state-of-the-art technology and industry-leading expertise, Creative Biolabs offers accurate and effective solutions for researchers who are committed to identifying predictive biomarkers. If you are interested in our services, please don't hesitate to contact us for more information and a detailed quote.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION